<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663867</url>
  </required_header>
  <id_info>
    <org_study_id>0071</org_study_id>
    <nct_id>NCT04663867</nct_id>
  </id_info>
  <brief_title>AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)</brief_title>
  <acronym>RESTOR-1</acronym>
  <official_title>Safety and Effectiveness Study of the AngioSafe Peripheral CTO Crossing System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AngioSafe, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Experien Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AngioSafe, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the safety and efficacy of the AngioSafe Peripheral CTO&#xD;
      Crossing System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to demonstrate the safety and effectiveness of the AngioSafe&#xD;
      Peripheral CTO Crossing System. The system facilitates the crossing of chronic total&#xD;
      occlusions (CTOs) in the peripheral arteries of lower limbs. A minimum of 70 subjects will be&#xD;
      treated across selected study enters within the U.S. and followed for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success is defined as Technical Success in the absence of device-related major adverse events through discharge or 24-hours post-procedure, whichever is sooner.</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success of AngioSafe Peripheral CTO Crossing System</measure>
    <time_frame>Procedure</time_frame>
    <description>Defined as the ability of catheter to facilitate placement of a guidewire into the distal lumen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success of AngioSafe Peripheral CTO Crossing System</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as Technical Success without a procedural complication within 30 days after the procedure. Procedural complication is defined as the need for open or repeat endovascular surgical repair in the treated limb, or a major bleeding event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of intraluminal CTO crossing facilitated by the Peripheral CTO Crossing System, as assessed by an Intravascular Ultrasound (IVUS).</measure>
    <time_frame>Procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral Artery Occlusion</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>AngioSafe Peripheral CTO Crossing System Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AngioSafe Peripheral CTO Crossing System</intervention_name>
    <description>The AngioSafe Peripheral CTO Crossing System is intended to facilitate the intraluminal placement of guidewires beyond stenotic lesions, including chronic total occlusions (CTOs) in the peripheral vasculature.</description>
    <arm_group_label>AngioSafe Peripheral CTO Crossing System Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to comply with protocol requirements and sign informed consent form&#xD;
&#xD;
          -  ≥ 22 years of age&#xD;
&#xD;
          -  Peripheral arterial disease defined by Rutherford Clinical Classification (Category&#xD;
             2-5)&#xD;
&#xD;
          -  Peripheral artery disease in target extremity is confirmed by imaging within 90 days&#xD;
             prior to Screening Committee submission (catheter angiography, computed tomographic&#xD;
             angiography (CTA), and/or magnetic resonance angiography (MRA))&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          -  Target lesion in native de novo common femoral artery (CFA), superficial femoral&#xD;
             artery (SFA), and/or popliteal artery&#xD;
&#xD;
          -  Vessel diameter(s) for target lesion is ≥ 3.0mm and ≤ 10mm&#xD;
&#xD;
          -  Target lesion is a severely stenosed segment of ≤ 200mm that involves the CTO(s)&#xD;
&#xD;
          -  Target lesion involves at least one CTO, i.e., is deemed as total occlusion (100%&#xD;
             stenosis)&#xD;
&#xD;
          -  At least one patent tibial vessel (≤ 70% stenosis) with run off to the foot&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic infection or an infection in extremity of target lesion&#xD;
&#xD;
          -  Target lesion within native vein or synthetic vessel grafts or in stent occlusion&#xD;
&#xD;
          -  Planned intervention in the contralateral limb during the study&#xD;
&#xD;
          -  Planned intervention in the target limb (other than target lesion) during the study&#xD;
&#xD;
          -  Coagulopathy or bleeding diatheses, thrombocytopenia with platelet count less than&#xD;
             50,000/μl, or INR &gt; 1.7&#xD;
&#xD;
          -  Antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated&#xD;
&#xD;
          -  Allergy to contrast agents or medications used to perform endovascular intervention&#xD;
             that cannot be adequately pre-treated&#xD;
&#xD;
          -  Allergy to nickel, titanium, urethane, nylon, or silicone&#xD;
&#xD;
          -  History of myocardial infarction within 30 days prior to enrollment/consent&#xD;
&#xD;
          -  History of stroke within 30 days prior to enrollment/consent&#xD;
&#xD;
          -  Chronic kidney disease (CKD) of stage 4 or greater based on an Estimated Glomerular&#xD;
             Filtration Rate (eGFR) &lt; 30ml/Min&#xD;
&#xD;
          -  Hemoglobin levels &lt;10g/dL verified by a lab test no older than 14 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Pregnant or nursing, for females of child-bearing potential (&lt; 50 years of age)&#xD;
&#xD;
          -  Participating in another interventional research study that may interfere with study&#xD;
             endpoints&#xD;
&#xD;
          -  Prior major amputation (above ankle) in target extremity&#xD;
&#xD;
          -  Acute limb ischemia (ALI)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subhash Banerjee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Texas Veterans Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mallik Thatipelli, MD</last_name>
    <phone>669-400-8383</phone>
    <email>mallik@angiosafe.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dignity Health - Chandler Regional Medical Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges Nseir, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Natalie Leon</last_name>
      <phone>480-728-8736</phone>
    </contact_backup>
    <investigator>
      <last_name>Georges Nseir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest Cardiovascular Associates</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Adventist Health St. Helena</name>
      <address>
        <city>Saint Helena</city>
        <state>California</state>
        <zip>94754</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer DeBattista</last_name>
      <email>DeBattJL@ah.org</email>
    </contact>
    <investigator>
      <last_name>Ehrin Armstrong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Mena-Hurtado, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Juan Carmona</last_name>
      <phone>203-785-2063</phone>
    </contact_backup>
    <investigator>
      <last_name>Carlos Mena-Hurtado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Klein, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Monica Faide</last_name>
      <phone>404-605-2823</phone>
    </contact_backup>
    <investigator>
      <last_name>Andrew Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Unzeitig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Shammas, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gail Shammas, BSN, CCRC</last_name>
      <phone>563-324-2828</phone>
    </contact_backup>
    <investigator>
      <last_name>Nicolas Shammas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Bunte, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Tina Baker</last_name>
      <phone>816-932-0364</phone>
    </contact_backup>
    <investigator>
      <last_name>Matthew Bunte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Lindsey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Laster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kimberly Campbell, APRN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Endovascular &amp; Amputation Prevention</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Rundback, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Kristen Hlozek, PhD</last_name>
      <email>kristen@lebecc.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Rundback, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Heart &amp; Vascular Institute</name>
      <address>
        <city>Matthews</city>
        <state>North Carolina</state>
        <zip>28105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Delgado, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Tara Villalta, RN</last_name>
      <phone>704-264-1388</phone>
    </contact_backup>
    <investigator>
      <last_name>Gabriel Delgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Hyder, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Nowak</last_name>
      <phone>401-793-5554</phone>
    </contact_backup>
    <investigator>
      <last_name>Omar Hyder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Soukas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellmont Cardiology Services</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Metzger, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Terrie Walker, MBA, BSN, RN</last_name>
      <phone>423-230-5643</phone>
    </contact_backup>
    <investigator>
      <last_name>Chris Metzger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA North Texas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirling Tsai, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Maria Mayen</last_name>
      <phone>214-857-3048</phone>
    </contact_backup>
    <investigator>
      <last_name>Shirling Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Subhash Banerjee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White, The Heart Hospital Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Das, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Julie Mccracken</last_name>
      <phone>469-814-4717</phone>
    </contact_backup>
    <investigator>
      <last_name>Tony Das, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sameh Sayfo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chadi Dib, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

